Juvenile generalized pustular psoriasis with IL36RN mutation treated with short‐term infliximab

A 8‐year‐old Chinese boy with generalized pustular psoriasis (GPP) refractory to cyclosporine and methylprednisolone was treated successfully with two infusions of infliximab 3.3 mg/kg. He remained in remission for 21 months. Direct sequencing of IL36RN gene showed a homozygous mutation, c.115 + 6T>C. Juvenile GPP is a rare severe form of psoriasis occasionally associated with life‐threatening complications. Like acitretin, cyclosporine and methotrexate, infliximab has been reported to be effective for juvenile GPP in case reports. However, there is a lack of data in the optimal treatment course of infliximab for juvenile GPP. Prolonged administration of these medications may cause toxic or fatal complications. We suggest that short‐term infliximab regimen should be recommended as a choice for acute juvenile GPP refractory to traditional systemic therapies. WBC count and CRP are sensitive parameters to reflect the disease activity and evaluate the effectiveness of treatment. Monitoring CD4 T lymphocyte count, preventing and correcting CD4 lymphocytopenia are important in the treatment course of juvenile GPP.

[1]  Hangfei Fu,et al.  Unprocessed interleukin-36α regulates psoriasis-like skin inflammation in co-operation with interleukin-1 , 2015, The Journal of investigative dermatology.

[2]  Fernanda Bellodi Schmidt,et al.  Biologic Response Modifiers and Pediatric Psoriasis , 2015, Pediatric dermatology.

[3]  C. Gabay,et al.  Regulation and function of interleukin‐36 cytokines in homeostasis and pathological conditions , 2015, Journal of leukocyte biology.

[4]  Michael Hölzel,et al.  IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions. , 2015, The Journal of investigative dermatology.

[5]  W. Weger,et al.  Childhood Generalized Pustular Psoriasis: Longtime Remission With Combined Infliximab and Methotrexate Treatment , 2015, Pediatric dermatology.

[6]  J. Kelsen,et al.  Infliximab Therapy in Pediatric Patients 7 Years of Age and Younger , 2014, Journal of pediatric gastroenterology and nutrition.

[7]  S. Brand,et al.  IL-36&ggr; Sustains a Proinflammatory Self-amplifying Loop with IL-17C in Anti-TNF–induced Psoriasiform Skin Lesions of Patients with Crohn's Disease , 2014, Inflammatory bowel diseases.

[8]  A. Griffiths,et al.  Infliximab-Induced Psoriasis and Psoriasiform Skin Lesions in Pediatric Crohn Disease and a Potential Association With IL-23 Receptor Polymorphisms , 2013, Journal of pediatric gastroenterology and nutrition.

[9]  Y. Shimomura,et al.  Acrodermatitis Continua of Hallopeau Is a Clinical Phenotype of DITRA: Evidence that It Is a Variant of Pustular Psoriasis , 2013, Dermatology.

[10]  K. Cordoro,et al.  The evolving role of biologics in the treatment of pediatric psoriasis. , 2013, Skin therapy letter.

[11]  M. Lebwohl,et al.  Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. , 2012, Journal of the American Academy of Dermatology.

[12]  A. Smahi,et al.  Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. , 2011, The New England journal of medicine.

[13]  R. Romiti,et al.  Generalized Pustular Psoriasis in Childhood , 2010, Pediatric dermatology.

[14]  M. Deschamps,et al.  Prolonged CD4 T cell lymphopenia increases morbidity and mortality after renal transplantation. , 2010, Journal of the American Society of Nephrology : JASN.

[15]  H. Antunes,et al.  Anti-TNF-α Therapy in Childhood Pustular Psoriasis , 2006, Dermatology.